argenx SE

$289.38
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.56 (+0.89%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell argenx SE and other stocks, options, and ETFs commission-free!

About ARGX

argenx SE American Depositary Shares, also called argenx SE, is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands. The listed name for ARGX is argenx SE American Depositary Shares.

CEO
Tim van Hauwermeiren
Employees
188
Headquarters
Breda, Noord-Brabant
Founded
2008
Market Cap
13.60B
Price-Earnings Ratio
Dividend Yield
Average Volume
153.52K
High Today
$291.23
Low Today
$285.71
Open Price
$286.33
Volume
124.20K
52 Week High
$291.23
52 Week Low
$103.75

Collections

ARGX Earnings

-$3.96
-$2.58
-$1.19
$0.19
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 25, Pre-Market

You May Also Like